Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Drug Makers Fire Back At Rebelling Sales Reps (India)

This article was originally published in PharmAsia News

Executive Summary

Indian drug makers are retaliating against sales representatives who accused them of exploitation and violations of government price caps. The Indian Drug Manufacturers Association, comprising more than 650 medium-size and small drug makers, has asked the Labor minister to reclassify the sales reps as "workmen" rather than as "medical representatives" considered a part of a company's management team. The proposed change is supported by the Organisation of Pharmaceutical Producers of India representing about 100 MNCs and Indian research-based pharmas. The Federation of Medical and Sales Representatives Associations of India also has been trying to get the government to govern their working conditions, such as requiring work days no longer than eight hours. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel